Introduzca una acción o criptomoneda en el cuadro de búsqueda para obtener un resumen
Entero Therapeutics, Inc.
ENTOEntero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis. It is also involved in the development of adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, currently under Phase 2 studies for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis; and niclosamide, an oral small molecule with anti-inflammatory inhibitor therapy, currently under Phase 2 studies for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, as well as immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients. The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024. Entero Therapeutics, Inc. was incorporated in 2014 and is based in Boca Raton, Florida. Address: 777 Yamato Road, Boca Raton, FL, United States, 33431
Analytics
Precio Objetivo de WallStreet
36 USDRelación P/E
–Rentabilidad por dividendo
–Año en curso
Año anterior
Trimestre actual
Último trimestre
Año en curso
Año anterior
Trimestre actual
Último trimestre
Cifras clave ENTO
Análisis de dividendos ENTO
Aumento del dividendo durante 5 años
–Crecimiento continuo
–Ratio de pago medio en 5 años
–Tendencia del payout ENTO
Valoración de la acción ENTO
Finanzas ENTO
Realice un seguimiento de las métricas clave de cada acción en un solo lugar y sin complicaciones
Hazte premiumResultados | 2019 | Dinámica |